Autolus Therapeutics Highlights Clincal Data, Says Findings Suggest 'Potential For Obe-cel Treatment Without The Need For Consolidative SCT'
Autolus Therapeutics Highlights Clincal Data, Says Findings Suggest 'Potential For Obe-cel Treatment Without The Need For Consolidative SCT'
Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces a poster presentation at the 2024 Lymphoma, Leukemia & Myeloma Congress being held October 16-19, 2024, in New York. These data suggest that adult patients with relapsed/refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL) achieve comparable outcomes irrespective of the timing of stem cell transplant (SCT) pre or post obe-cel, suggesting no further benefit of consolidative transplant based on this post-hoc analysis. Additionally, obe-cel given as a sole treatment to patients with lower Tumor Burden (TB) at Lymphodepletion (LD) was associated with better outcomes.
Autolus Therapeutics plc（納斯達克：AUTL）是一家臨床階段的生物製藥公司，致力於開發下一代編程t細胞療法，宣佈將在2024年10月16日至19日在紐約舉行的2024年淋巴瘤、白血病 & 骨髓瘤大會上進行海報展示。這些數據表明，復發/難治性B細胞急性淋巴細胞白血病（r/r b-ALL）的成年患者無論在幹細胞移植（SCT）之前還是之後obe-電芯治療，都能獲得可比的結果，表明在這個事後分析中，鞏固性移植的進一步益處不大。此外，obe-電芯作爲唯一治療方案應用於術前淋巴清除（LD）時腫瘤負擔較低的患者，與更好的預後相關聯。
譯文內容由第三人軟體翻譯。
